Abstract
Recent advances in genetics, molecular biology, molecular pharmacology, and biomolecular technology have brought targeted therapeutic opportunities to the forefront of clinical development. Physician and patient communities are highly attracted to lung cancer management opportunities that may involve a personalized approach based on utilizing a unique cancer signal with a target-specific therapy. In this chapter, we will review several advanced clinical developments involving gene-based targeted therapies in lung cancer. Discussion will focus on replacement therapies for abnormal p53 function, FUS1 mediated molecular therapy, antisense technologies, and early developments with RNA interference technology.KeywordsGeneMolecularLungCancer therapy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
